Press Release

Increase in the prevalence of Anaphylaxis & Other Food Allergies and Growing demand for home healthcare will drive the Autoinjectors Market

December, 2018

" "

The global autoinjectors market is expected to witness a CAGR of 17.1% during the forecast period to reach revenue of $10,012.0 million by 2024

 Bangalore, India, November 14, 2018: With its recently published study “Autoinjectors Market - Global Drivers, Restraints, Opportunities, Trends, and Forecast up to 2024”, Infoholic Research forecasts that the global market for autoinjectors will grow, owing to the increasing incidence rate of anaphylaxis & other food allergies, technological advancements in autoinjector devices, and growing home healthcare. According to the estimation of the European Academy of Allergy and Clinical Immunology (EAACI), in 2015, around 17 million people were suffering from food allergies, among which approximately 3.5 million were children in the UK. The other essential features providing an opportunity for the development of the autoinjectors market include novel formulations of the drugs and the favorable government policies. Recently, the UK regulator expanded the expiry date of EpiPens by three months to overcome the shortage of the device, as EpiPens accounted for three-fourth of the 340,000 adrenaline autoinjectors prescribed per annum. Recent product recalls by the companies and the availability of alternatives for autoinjectors are hindering the market growth.

The regions covered in the report are North America, Europe, Asia Pacific, and Rest of the World (RoW). North America is the leader in the autoinjectors market, followed by Europe, Asia Pacific, and Rest of the World. More than 35% of the market is occupied by North America, with the US being the major contributor to the market growth.
The major companies in the industry are focused on various marketing strategies to improve their geographical reach. Numerous players are focusing on increasing awareness about the disease conditions and advanced devices available in the market. A majority of the companies are rebranding their autoinjectors with worthwhile reductions in the price. In December 2016, Mylan introduced the EpiPen generic version to offer autoinjector devices for patients at reduced prices. This method ought to help the company in aiming a bigger customer pool, thus increasing their customer base.” – Rikitha K Murthy, Research Analyst, Infoholic Research

Key insights of the report include:

  • Product Type:

    • Disposable Autoinjectors

    • Reusable Autoinjectors

  • Application Type:

    • Anaphylaxis

    • Multiple Sclerosis

    • Rheumatoid Arthritis

    • Diabetes

    • Others

  • Regional Analysis:

    • North America

    • Europe

    • Asia Pacific

    • Rest of the World

  • Industry Outlook: Market trends, drivers, restraints, and opportunities


Mr. Karthick Subramani

Infoholic Research LLP

Marketing & Communication